InvestorsHub Logo
Followers 19
Posts 334
Boards Moderated 0
Alias Born 07/25/2016

Re: pix post# 1193

Wednesday, 11/16/2016 10:56:46 AM

Wednesday, November 16, 2016 10:56:46 AM

Post# of 6042
The abstract provides just a glimpse. In this case, the composite RFS and carcinoma in-situ RFS suggests to me that HTBX's vaccine is likely not inferior to BCG, otherwise the percentages would be lower. The two immunotherapies appear to be synergistic and the addition of HTBX's immunotherapy to BCG is likely improving regression free survivals in a patient population that observes up to 90% regressions over 5 year periods.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News